Idalopirdine (Lu AE58054) is a Serotonin 6 receptor (5-HT6) antagonist. Idalopirdine exrets good oral bioavailability and robust efficacy in a rat model of cognitive impairment in schizophrenia. In rats idalopirdine potentiates the effects of acetylcholinesterase inhibitor donepezil on two pharmacodynamic biomarkers associated with cognition, i.e. neuronal oscillations and extracellular ACh levels in the hippocampus. Such potentiation could contribute to the procognitive effects of idalopirdine observed in donepezil-treated Alzheimer's disease patients. The compound is being developed by Lundbeck as an adjunctive therapy with acetylcholinesterase inhibitor donepezil, and is in phase III development for the treatment of Alzheimer's disease in multiple countries worldwide. A phase II trial for the treatment of cognitive impairment associated with schizophrenia was conducted; however no recent reports of development for idalopirdine have been identified.

Tetrahydrocannabivarin is a propyl analogue of tetrahydrocannabinol that acts as a Cannabinoid receptor type 1 antagonist and a partial agonist of Cannabinoid receptor type 2. Beyond the endocannabinoid system, Tetrahydrocannabivarin has also been reported to activate 5HT1A receptors to produce an antipsychotic effect that has therapeutic potential for ameliorating some of the negative, cognitive and positive symptoms of schizophrenia. Animal studies have shown that, like rimonabant, Tetrahydrocannabivarin reduces weight gain and food consumption in non-fasted mice but does not increase activity in the brain regions involved in emotion regulation. In another study, involving diet-induced obese mice, oral Tetrahydrocannabivarin reduced body fat content, increased energy expenditure, and reduced fasting insulin and 30-min insulin response to oral glucose tolerance test. In clinical trials THCV significantly decreased fasting plasma glucose and improved pancreatic β-cell function.

Viqualine (also known as PK 5078) was developed as an antidepressant; however, it has never been marketed. Viqualine acts as an inhibitor of the serotonin reuptake and release and possesses diazepam-like actions. In addition, was studied the ability of this compound to reduce alcohol consumption and that was not an antidepressant effect.

Antineoplaston A10 is a piperidinedione antineoplaston with potential antineoplastic activity. Antineoplaston A10 was originally isolated from human urine but is now synthetically derived. This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis. Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. Antineoplaston A10 has been used in trials studying the treatment of glioma, sarcoma, lymphoma, lung cancer, liver cancer, and kidney cancer, among others.

UK-390957 is a selective serotonin reuptake inhibitor (SSRI) that was in phase II/III development in the USA, European Union and other territories with Pfizer, for the treatment of Premature ejaculation. UK-390957 represented a major development in sexual medicine, and offered patients the convenience of on-demand dosing, significant improvements in IELT, ejaculatory control, and sexual satisfaction with minimal adverse effects. However development of UK-390957 was discontinued.

Cyclindole is a tryptamine derivative in which the aminoethyl side-chain has been cyclized. Clinical trials of the drug have demonstrated antidepressant activity. The drug also possesses neuroleptic properties and acts as an antagonist of the D2 receptor.

There is no information in the scientific papers related to the biological properties of risocaine (also known as n-propyl 4-aminobenzoate). However, exists mention, that it is used as a local anesthetic.

Parbendazole is a potent inhibitor of microtubule assembly that was studied as an anthelmintic agent. Information about the current use of this drug is not available.

Taglutimide is a norbornane derivative patented by Kwizda, F. Joh., Chemische Fabrik as the sedative-hypnotic compound. In preclinical studies, Taglutimide did not produce any toxic effects when administered orally to mice even at a very high dosage. Central-nervous depression was demonstrated by a reduction in spontaneous motor activity, potentiation of the central-depressant effect of pentobarbital, antagonism of the central-stimulant effect of amphetamine after oral administration and by narcotic activity after i.v. administration of the drug. Furthermore, oral administration of Taglutimide potentiated the analgesic action of morphine without being effective on its own.